Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.04.16.718601

A TRANSLATIONAL LC-MS/MS FRAMEWORK FOR LIPID BIOMARKER IDENTIFICATION AND QUANTIFICATION IN HUMAN PLASMA

Abstract

Lipid metabolism is increasingly recognized as a hallmark of cancer, yet translating lipidomic discoveries into clinically actionable biomarkers remains constrained by analytical variability and limited standardized validation frameworks. This challenge is further compounded by a chicken-or-egg problem, where expensive standards and labelled internal standards are required to identify and quantitate target lipids, but the diagnostic importance of these targets is uncertain until they can be reliably measured. Previous work had indicated the potential of 48 lipid biomarker species for the prediction of breast cancer from plasma samples using high resolution liquid chromatography mass spectrometry. This study aimed to identify each of these 48 species and develop a quantitative method to determine the absolute concentrations of these lipids in plasma to provide the basis for the development of a clinical assay for use in breast cancer detection. In doing so, we present a pragmatic workflow that bridges lipid discovery with lipid identification and robust quantitative analysis. A curated library of 48 lipid species was established using authentic standards to verify plasma lipids through retention-time matching and high-resolution spectral comparison. In plasma, 41 lipids were confidently identified based on co-elution with standards and diagnostic fragment ions. Method qualification, including assessment of accuracy, precision, recovery, and linearity, was performed across all 48 lipids in parallel with identification, and 46 lipids ultimately met all predefined qualification criteria. Notably, practical constraints, including time, cost, and availability of authentic standards, necessitated performing identification and targeted method development in parallel, highlighting challenges inherent to translating lipidomics into commercial or clinical assays. This workflow provides a reproducible framework for harmonizing lipid identification and quantification, enabling the reliable integration of lipidomic data into biomarker discovery and clinical applications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

David, M., Adam, K.-P., Li, D., Lim, X. Y., Hurrell, J. G. R., Preston, S., Peake, D. A., Batarseh, A.. 2026-04-21. A TRANSLATIONAL LC-MS/MS FRAMEWORK FOR LIPID BIOMARKER IDENTIFICATION AND QUANTIFICATION IN HUMAN PLASMA. https://doi.org/10.64898/2026.04.16.718601

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Deep reinforcement learning-driven discovery of a MsbA-targeted small-molecule antibiotic for the treatment of Acinetobacter baumannii infection

Antibiotics with new mechanisms are highly pursued to address the threat of infections caused by drug-resistant Gram-negative bacteria. Targeting MsbA, a key protein of the lipopolysaccharide biosynthesis pathway, represents a promising strategy to discover new classes of antibiotics. However, currently available MsbA-targeted molecules either lack sufficient potency or have unfavorable properties, necessitating expansion of chemical space. In this study, we chose the most promising cerastecin Cpd 4 as the template, and used two Artificial Intelligence (AI)-based tools, i.e. Link-INVENT and AutoMolDesigner for molecular design, performed chemical derivatization and antibacterial activity evaluation, which led to the discovery of Y-11 (MIC for A. baumannii: 0.5 g/mL). Encouragingly, Y-11 showed equivalent potency to Cpd4 for carbapenem-resistant A. baumannii, and less cytotoxicity and hemolysis as well as lower spontaneous resistance frequency. In vivo efficacy study demonstrated that Y-11 could effectively reduce bacterial loads in the mice infected by A. baumannii. The following mechanism study including molecular dynamics simulation, biochemical assay, and transmission electron microscope (TEM) analysis suggested that Y-11 inhibited the transport of lipooligosaccharide and impaired the formation of outer membrane, probably by competitively binding to the substrate binding site of MsbA and modulating ATPase activity. Taken together, we have discovered a MsbA-targeted small molecule Y-11 via AI-driven drug design, which provides a foundation for future antibiotic development.

biochemistry↗

Dynamic architecture of the Rixosome reveals mechanism of activation and ITS2 processing

Eukaryotic ribosome assembly requires the coordinated processing and extensive remodeling of pre-rRNAs. During late nuclear maturation of the 60S subunit, sequential removal of the internal transcribed spacer 2 (ITS2) is initiated by endonucleolytic cleavage at site C2 by the conserved Las1 nuclease. Las1 acts together with the kinase Grc3 and the Rix1 complex to form the Rixosome, which also functions in transcriptional regulation. However, the assembly of the Rixosome, its recruitment to pre-ribosomes, and its activation for ITS2 cleavage remain unclear. Here, we present cryo-EM structures of the human LAS1 complex, two structures of the isolated Rixosome and nine transition states of Rix1-bound pre-60S particles from Schizosaccharomyces pombe. These structures reveal a dynamic Rixosome architecture in which the heterotetrameric Las1 complex engages one or two copies of the Rix1 complex. Rix1 binding is highly flexible in the human Rixosome but rigid in the yeast complex. The isolated yeast Rixosome remains inactive, but binding to the pre-60S particle triggers a structural rearrangement that allows for substrate engagement and activation of the nuclease. Together, our results define the dynamic architecture of the Rixosome and provide a structural framework for ITS2 processing during nuclear maturation of the eukaryotic 60S ribosomal subunit.

biochemistry↗

SGFP-Grid Split GFP Graphene Grids

Affinity graphene grids provide a promising approach for selective protein capture in cryo-EM. Here, we introduce a split-GFP graphene grid platform(SGFP-G), in which graphene-conjugated GFP 1-10 selectively captures GFP11 tagged proteins from low concentration samples or cell lysates. This platform enables rapid assessment of target protein enrichment and particle distribution before vitrification via fluorescence imaging, while the grid design positions captured proteins away from the graphene surface and air-water interface. We also introduce a unique strategy to minimize nonspecific protein adsorption, thereby improving the selective enrichment of target proteins on this grid. Using GFP11-tagged apoferritin, we demonstrate fluorescence guided protein capture and obtain a 2.58 [A] cryoEM reconstruction, establishing SGFP-G as an affinity grid platform for high resolution structural studies with reduced sample requirements.

biochemistry↗